Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL377381 | 0.79 | HTR6 (0.50) | HTR6ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL544207 | 0.78 | HTR6 (0.55) | HTR6ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL6172350 | 0.76 | HTR6 (0.52) | HTR6ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL3520533 | 0.76 | CA1 (0.55) | HTR6ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL7292002 | 0.74 | HTR6 (0.50) | HTR6ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL17808674 | 0.74 | HTR6 (0.50) | HTR6ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL2687422 | 0.74 | ALDH1A1 (0.52) | HTR6ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL2134610 | 0.74 | HTR6 (0.50) | HTR6ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL9398028 | 0.74 | TSHR (0.52) | HTR6ALDH1A1KDM4EMAPTLMNA | |
| SCHEMBL6717470 | 0.74 | HTR6 (0.50) | HTR6ALDH1A1KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590333-A4 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | CRYSTALGENOMICS INC (KR) | 2008-04-30 | — | — | EP | claimed |
| US-7179832-B2 | Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2007-02-20 | — | — | US | claimed |
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2006-04-13 | — | — | US | claimed |
| EP-1590333-A1 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | Crystalgenomics, Inc. (KR) | 2005-11-02 | — | — | EP | claimed |
| WO-2004065370-A1 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | CRYSTALGENOMICS, INC. (KR) | 2004-08-05 | — | — | WO | claimed |
| EP-1023295-A4 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO INC (US) | 2001-01-24 | — | — | EP | claimed |
| EP-1061934-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-12-27 | — | — | EP | claimed |
| EP-1023295-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | Merck & Co., Inc. (US) | 2000-08-02 | — | — | EP | claimed |
| US-5981584-A | USEFUL IN THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING THE AGGREGATION OF BLOOD PLATELETS, INHIBITING ANGIOGENESIS, INHIBITING OSTEOCLAST MEDIATED BONE RESORPTION, PREVENTING PLATELET THROMBOSIS | MERCK & CO., INC. (US) | 1999-11-09 | — | — | US | claimed |
| WO-1999045939-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-09-16 | — | — | WO | claimed |
| WO-1998034935-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO., INC. (US) | 1998-08-13 | — | — | WO | claimed |
| EP-1590333-A4 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | CRYSTALGENOMICS INC (KR) | 2008-04-30 | — | — | EP | disclosed |
| US-7179832-B2 | Glycogen synthase kinase 3β inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2007-02-20 | — | — | US | disclosed |
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | CRYSTALGENOMICS, INC. (KR) | 2006-04-13 | — | — | US | disclosed |
| EP-1590333-A1 | GLYCOGEN SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF | Crystalgenomics, Inc. (KR) | 2005-11-02 | — | — | EP | disclosed |
| US-6117842-A | INHIBITION OF BINDING OF FIBRINOGEN AND OTHER PROTEINS TO BLOOD PLATELETS, AND INHIBITING AGGREGATION OF BLOOD PLATELETS; | MERCK & CO., INC. (US) | 2000-09-12 | — | — | US | disclosed |
| EP-1023295-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | Merck & Co., Inc. (US) | 2000-08-02 | — | — | EP | disclosed |
| US-5981584-A | USEFUL IN THE MANUFACTURE OF A MEDICAMENT FOR INHIBITING THE AGGREGATION OF BLOOD PLATELETS, INHIBITING ANGIOGENESIS, INHIBITING OSTEOCLAST MEDIATED BONE RESORPTION, PREVENTING PLATELET THROMBOSIS | MERCK & CO., INC. (US) | 1999-11-09 | — | — | US | disclosed |
| WO-1999045939-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1998034935-A1 | FIBRINOGEN RECEPTOR ANTAGONIST PRODRUGS | MERCK & CO., INC. (US) | 1998-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079521-A1 | Glycogen synthase kinase 3beta inhibitor, composition and process for the preparation thereof | GSK3B, GSK3A, GYS2 | HTR6 4039/4885ALDH1A1 3930/4885KDM4E 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.